Betamipron

Betamipron

SCHEMBL605899

O=C(O)CCNC(=O)c1ccccc1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 1/20 0.70
CTSG P08311 1/20 0.70
CTRB1 P17538 1/20 0.70
CMA1 P23946 1/20 0.70
GAA P10253 1/20 0.63
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
SMN1; SMN2 Q16637 4/20 0.61
LMNA P02545 2/20 0.61
MAPK1 P28482 1/20 0.61
POLB P06746 1/20 0.61
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
EPHX2 P34913 1/20 0.59
HDAC3 O15379 3/20 0.58
HDAC4 P56524 3/20 0.58
HDAC1 Q13547 3/20 0.58
HDAC7 Q8WUI4 3/20 0.58
HDAC2 Q92769 3/20 0.58
HDAC10 Q969S8 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Betamipron SCHEMBL4498475 1.00 PRSS1 (0.70) PRSS1CTSGCTRB1CMA1GAA
SCHEMBL9717434 0.91 MAPK1 (0.71) PRSS1CTSGCTRB1CMA1GAA
SCHEMBL2033165 0.88 MAPK1 (0.73) PRSS1CTSGCTRB1CMA1GAA
SCHEMBL9717417 0.88 ITGB3 (0.65) PRSS1CTSGCTRB1CMA1GAA
SCHEMBL9829615 0.87 GAA (0.57) PRSS1CTSGCTRB1CMA1GAA
SCHEMBL3192014 0.87 LMNA (0.77) PRSS1CTSGCTRB1CMA1GAA
Betamipron SCHEMBL28084518 0.87 NPC1 (0.73) PRSS1CTSGCTRB1CMA1SMN1; SMN2
SCHEMBL950223 0.86 MAPK1 (0.83) PRSS1CTSGCTRB1CMA1GAA
SCHEMBL2324530 0.86 PRSS1 (0.64) PRSS1CTSGCTRB1CMA1GAA
SCHEMBL5592824 0.86 PRSS1 (0.68) PRSS1CTSGCTRB1CMA1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1896 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12544359-B2 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors Infex Therapeutics Limited (GB) 2026-02-10 US claimed
WO-2025264604-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME THE PROCTER & GAMBLE COMPANY (US) 2025-12-26 WO claimed
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME PROCTER & GAMBLE (US) 2025-12-18 US claimed
CN-119100967-A 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors 英菲克斯治疗有限公司 2024-12-10 CN claimed
CN-114728902-B 1-Aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors 英菲克斯治疗有限公司 2024-09-13 CN claimed
US-20240216410-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER THERAPY-INDUCED NEUTROPENIC FEVER AND/OR GVHD BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-07-04 US claimed
WO-2024123562-A2 PEPTIDE INHIBITORS OF BETA-LACTAMASE THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2024-06-13 WO claimed
EP-4314255-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER THERAPY-INDUCED NEUTROPENIC FEVER AND/OR GVHD Board of Regents, The University of Texas System (US) 2024-02-07 EP claimed
US-20230414584-A1 ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASIS CENTRE FOR DIGESTIVE DISEASES (AU) 2023-12-28 US claimed
CN-115463128-B Panipenem and betamilone compound combination drug for injection and preparation method thereof 深圳太太药业有限公司 2023-10-03 CN claimed
CN-1036832-C Composition containing a penem or carbapenem artibiotic and the use of the same SANKYO CO (JP) 1997-12-31 CN claimed
US-5044091-A Frozen first and second liquid freeze dried together SANKYO COMPANY, LIMITED (JP) 1991-09-03 US claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN claimed
EP-0029284-B1 METHOD FOR THE ELECTROPHORETIC SEPARATION OF PROTEINS, A BUFFER SOLUTION AND BUFFER COMPOSITIONS THEREFOR GELMAN SCIENCES, INC. (US) 1984-02-15 EP claimed
US-4292162-A A SOLUTION OF TRIS BUFFER, HIPPURIC ACID, AND A WATER-SOLUBLE HIPPURATE GELMAN SCIENCES, INC. (US) 1981-09-29 US claimed
US-4292154-A USING A UREA-, AN AMIDE-, OR AMINOCARBOAMIDE-CONTAINING CARBOXYLIC ACID AND THE CORRESPONDING ACID SALT GELMAN SCIENCES, INC. (US) 1981-09-29 US claimed
EP-0029284-A1 Method for the electrophoretic separation of proteins, a buffer solution and buffer compositions therefor GELMAN SCIENCES, INC. (US) 1981-05-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544359-B2 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors CBR1, CBR3, SRR PRSS1 709/4885CTSG 1926/4885CTRB1 148/4885
US-20250381110-A1 SKIN CARE COMPOSITION AND METHOD OF USING THE SAME SQSTM1, BECN1, CUTA PRSS1 4138/4885CTSG 213/4885CTRB1 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.